机构：[1]Department of Pulmonary Disease, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China[2]Hunan Cancer Hospital, Changsha, China[3]Department of Thoracic Medical Oncology, Beijing Cancer Hospital, Beijing, China[4]Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[5]Hainan General Hospital, Haikou, China[6]Department of Thoracic Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University (Hunan Cancer Hospital), Changsha, China[7]Fuzhou Pulmonary Hospital in Fujian Province, Fuzhou, China[8]Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[9]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China[10]Nantong Tumor Hospital, Nantong, China[11]First Affiliated Hospital Of Gannan Medical University, Ganzhou, China[12]The First Affiliated Hospital of Xiamen University, Xiamen, China[13]Department of Respiratory Disease, Anhui Provincial Hospital, Hefei, China[14]Jiangxi Province Hospital, Nanchang, China[15]Department of Oncology, Affiliated Hospital of Medical College, Qingdao University, Qingdao, China[16]Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院肿瘤内科临床科室[17]Affiliated tumor hospital, Guangzhou medicine university, Guangzhou, China[18]Beijing Chest Hospital, Capital Medical University, Beijing, China[19]Harbin Medical University Cancer Hospital, Harbin, China[20]The General Hospital of the People's Liberation Army, Beijing, China
第一作者机构：[1]Department of Pulmonary Disease, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
推荐引用方式(GB/T 7714)：
Han Baohui,Chen Jianhua,Wang Ziping,et al.Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.[J].JOURNAL OF CLINICAL ONCOLOGY.2021,39(15):doi:10.1200/JCO.2021.39.15_suppl.e21072.
APA：
Han, Baohui,Chen, Jianhua,Wang, Ziping,Li, Xingya,Wang, Lin...&Jiang, Da.(2021).Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer..JOURNAL OF CLINICAL ONCOLOGY,39,(15)
MLA：
Han, Baohui,et al."Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.".JOURNAL OF CLINICAL ONCOLOGY 39..15(2021)
医学